Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors
Notably, data for AstraZeneca's Lynparza, Johnson & Johnson's Zytiga, and Loxo Oncology's larotrectinib highlights the move toward specialized medicine.
Putting aside the hype around combination immunotherapies, concerns remain about overall response rates for these drugs.
The executive director of oncology marketing is fascinated by the resilience of the human body.
Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation
Industry leaders discussed why a social-centric approach is especially important in oncology, particularly as it relates to health systems, interactions with healthcare providers, and family support.
This includes concerns about the effectiveness — and cost-effectiveness — of drugs like Merck's Keytruda and Bristol-Myers Squibb's Opdivo, in combination or alone.
BMS partners on Opdivo combo; one-quarter of insurers have signed an outcomes-based contract with a drugmaker; rebates do not lead to savings for Medicare beneficiaries
Keytruda receives first approval based on a genetic feature and not tumor's location; Alexion reps reportedly crossed ethical lines; profits up at insurers
An FDA advisory committee is expected to decide Wednesday whether to recommend neratinib for approval.
Keytruda gets two new FDA approvals; lawmakers aim to speed up approval of generics; Incyte uses soap opera to spread rare-disease awareness
Docs spend little time telling patients about cancer costs; Shire to file hereditary angioedema drug with the FDA by 2018; Philips CEO on access obstacles
Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.
FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs
Pfizer to provide Ibrance for free during NICE analysis; the FDA approves new ALS drug; people turn to Twitter to tell stories about pre-existing conditions
Novartis gets Breakthrough designation for its CAR-T therapy; Duchesney continues working with Kardashian; new user-fee deal to speed up FDA approvals
A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.
Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose
Diane Jooris is co-founder and CEO of OnComfort.
Dr. Christiana Bardon is managing director of the Oncology Impact Fund for MPM Capital.
Renee Rodgers is executive director and head of digital strategy for U.S. oncology at Novartis.
Brandi Davis-Dusenbery is CEO of Seven Bridges.
Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall
Novartis CAR-T drug receives priority review; addiction center's ad compares addiction to cancer; Arizona passes off-label law
Ovarian cancer drug nabs FDA approval; Senate committee to investigate opioid manufacturers; Allergan's acne drug reports positive Phase-III results
A high-profile cancer track commands attention, while wearables and IBM Watson Health come under fire.
Novartis' Gleevec shows long-term survival benefit in study; Novo Nordisk CEO considers small acquisitions; Merck KGaA to sell biosimilars unit
Harvard Pilgrim signs pay-for-performance deals with Lilly and Amgen; new advocacy group wants lower drug prices; Zykadia gets priority review
Few questions give healthcare marketers more heart palpitations than this one: "How do you know it will work?"
Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.